Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

By S. Yusuf, J. Bosch, G. Dagenais, Jun Zhu, D. Xavier, Li-sheng Liu, P. Pais, P. López-Jaramillo, Lawrence A Leiter, A. Dans and 23 more. New England Journal of Medicine, 2016

744 citations recorded by the source corpus.

Subfields: Cancer Research, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/8129d14fb1558dd0c81e7ece59b9cf7f64550dcf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. J. Armitage
2. George Davey Smith
3. R. Collins
4. M. Law
5. P. Ridker

In Endocrinology, Diabetes and Metabolism

1. J. Armitage
2. George Davey Smith
3. P. Poirier
4. P. Ridker
5. Massimo F. Piepoli
6. V. Basevi
7. Peter Libby
8. I. Graham

In Surgery

1. J. Armitage
2. George Davey Smith
3. R. Collins
4. M. Law
5. P. Ridker
6. I. Graham
7. Peter Libby
8. Massimo F. Piepoli

Citations in the corpus

• Interpretation of the evidence for the efficacy and safety of statin therapy. (2016, methodology): “That limitation can now be avoided by linking web-tabulations of all recorded adverse events to the journal article, as was done recently for the THRIVE trial of niacin(41) and HOPE-3 trial of rosuvastatin 10 mg daily.(192) Such tabulations have also been provided for the Heart Protection Study of s”
• 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. (2016, result): “9 mmol/L reduction in LDL-C resulted in a 25% reduction in events (NNT 1⁄4 70).(44) Also of importance was the fact that 49% of the HOPE-3 population was Asian, with outcomes similar to those in the Caucasian population, increasing the evidence for primary prevention in this population.”
• Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association (2019, neutral): “23).(75) Results from the various trials and the major meta-analyses are provided in Table 4.”